hrcak mascot   Srce   HID

Ostalo

Successful Management of Ustekinumab-Induced Pustular Psoriasis without Therapy Discontinuation

Nina Caca-Biljanovska
Marija V'lckova-Laskoska ; University of Skopje, Skopje, Macedonia
Dimitri Laskoski

Puni tekst: engleski, PDF (238 KB) str. 202-202 preuzimanja: 294* citiraj
APA 6th Edition
Caca-Biljanovska, N., V'lckova-Laskoska, M. i Laskoski, D. (2013). Successful Management of Ustekinumab-Induced Pustular Psoriasis without Therapy Discontinuation. Acta Dermatovenerologica Croatica, 21 (3), 202-202. Preuzeto s https://hrcak.srce.hr/109930
MLA 8th Edition
Caca-Biljanovska, Nina, et al. "Successful Management of Ustekinumab-Induced Pustular Psoriasis without Therapy Discontinuation." Acta Dermatovenerologica Croatica, vol. 21, br. 3, 2013, str. 202-202. https://hrcak.srce.hr/109930. Citirano 22.10.2021.
Chicago 17th Edition
Caca-Biljanovska, Nina, Marija V'lckova-Laskoska i Dimitri Laskoski. "Successful Management of Ustekinumab-Induced Pustular Psoriasis without Therapy Discontinuation." Acta Dermatovenerologica Croatica 21, br. 3 (2013): 202-202. https://hrcak.srce.hr/109930
Harvard
Caca-Biljanovska, N., V'lckova-Laskoska, M., i Laskoski, D. (2013). 'Successful Management of Ustekinumab-Induced Pustular Psoriasis without Therapy Discontinuation', Acta Dermatovenerologica Croatica, 21(3), str. 202-202. Preuzeto s: https://hrcak.srce.hr/109930 (Datum pristupa: 22.10.2021.)
Vancouver
Caca-Biljanovska N, V'lckova-Laskoska M, Laskoski D. Successful Management of Ustekinumab-Induced Pustular Psoriasis without Therapy Discontinuation. Acta Dermatovenerol Croat. [Internet]. 2013 [pristupljeno 22.10.2021.];21(3):202-202. Dostupno na: https://hrcak.srce.hr/109930
IEEE
N. Caca-Biljanovska, M. V'lckova-Laskoska i D. Laskoski, "Successful Management of Ustekinumab-Induced Pustular Psoriasis without Therapy Discontinuation", Acta Dermatovenerologica Croatica, vol.21, br. 3, str. 202-202, 2013. [Online]. Dostupno na: https://hrcak.srce.hr/109930. [Citirano: 22.10.2021.]

Sažetak

We present a 34-year-old female patient with methotrexate unresponsive longstanding plaque psoriasis who developed pustular psoriasis ten weeks after initiation of ustekinumab therapy. Given the lack of other side effects and the rapid initial response of the underlying plaque psoriasis we opted against discontinuing ustekinumab therapy. Topical corticosteroids were added for the management of the pustular lesions on initial presentation. Given the treatment-resistant nature of our patient’s underlying plaque psoriasis, we chose dose-intense regimen (every 8 weeks). After successful remission of the pustular lesions, topical corticosteroids were discontinued. Following nearly complete clearance of the underlying plaque psoriasis, maintenance ustekinumab therapy at the recommended 12-week intervals was initiated starting week 28. No recurrence of pustular psoriasis was noted in our 18-month follow-up. Our experience shows that pustular lesions associated with ustekinumab can be successfully managed with topical corticosteroids without discontinuing ustekinumab therapy and compromising the therapeutic benefit seen with underlying condition.

Ključne riječi
ustekinumab; adverse events; pustular psoriasis; plaque psoriasis

Hrčak ID: 109930

URI
https://hrcak.srce.hr/109930

Posjeta: 516 *